Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Germany-based Geneart has received a patent that protects the use of certain custom-designed HIV gene sequences for the development of therapeutics or vaccines in the following countries: Austria, Belgium, France, Germany, Great Britain, Italy, Luxembourg, the Netherlands, Spain and Switzerland.
Subscribe to our email newsletter
The patent describes gene sequences, which have already been tested as HIV vaccine candidates in a Phase I clinical trial. Currently, the gene sequences are tested in a Phase I/II trial by the EuroVacc Foundation. As a licensor, Geneart provides the patented gene sequences for these trials.